Metrics as of 10/16/2026, 05:40 AM (Berlin time), refresh in progress.
DiaMedica Therapeutics Stock
DiaMedica Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Dietrich John Pauls
- Employees
- 35
- Market cap
- $434 M
- IPO
- 03/08/2012
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy…
DiaMedica Therapeutics stock: price history
1D
+5.0%
1W
+0.4%
1M
+23.1%
6M
+21.5%
YTD
+1.0%
1Y
+14.0%
2Y
+80.7%
5Y
+96.1%
10Y
+104.1%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~19% weaker price swings than usual
Ask the agents about DiaMedica Therapeutics
Analyst assessment of DiaMedica Therapeutics
PRICE TARGET LOW
US$7.00
CONSENSUS
US$8.33
MEDIAN
US$8.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 11/08/2026
DiaMedica Therapeutics stock metrics
P/E
-11.17
P/B
11.3
EV/EBITDA
-11.44
RETURN ON EQUITY
-26.4%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
46.9%
FLOAT SHARES
25,298,701
AVG. DAILY VOLUME (30D)
219,212
Insider transactions (SEC)
Pauls Dietrich John
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about DiaMedica Therapeutics stock
What does DiaMedica Therapeutics do?
DiaMedica Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Dietrich John Pauls, the company employs around 35 people.
The IPO was on 03/08/2012; the stock trades on NASDAQ under the ticker DMAC.
What do analysts say about DiaMedica Therapeutics stock?
6 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$8.33, ranging from US$7.00 to US$10.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does DiaMedica Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -19% stronger than usual.
Does DiaMedica Therapeutics pay a dividend?
No, DiaMedica Therapeutics currently does not pay a dividend.
Which stocks are comparable to DiaMedica Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get DiaMedica Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess DiaMedica Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.